The company ended the year with cash totaling $3.7M, compared to $7.5M as of December 31, 2023. The company raised a total of $6.6M of gross proceeds under its ATM financing program for the year ended December 31, 2024.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACXP:
- Acurx to sell 2.745M shares at 40c in registered direct offering
- Biotech Alert: Searches spiking for these stocks today
- Acurx’s ibezapolstat shows efficacy in CDI treatment
- Acurx new patent granted by JPO related to DNA Polymerase IIIC Inhibitors
- Acurx files to sell 2.61M shares of common stock for holders